Vir Biotechnology
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 4 days.
- Recent price momentum is +21.0% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 100.0% | Better than 99% |
| Operating margin | -720.9% | Better than 3% |
| Net margin | -658.4% | Better than 3% |
| Return on equity | -45.7% | Better than 10% |
| Return on invested capital | -44.3% | Better than 7% |
Momentum B-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -14.2% | Better than 41% |
| 6-month return | -8.7% | Better than 42% |
| 12-month return (ex latest month) | 86.1% | Better than 94% |
| Distance below 52-week high | 41.7% | Better than 27% |
Financial Health A+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 5.5x | Better than 88% |
| Debt to assets | 9.8% | Better than 70% |
| Free cash flow / net income | 309.2% | Better than 86% |
Analyst View A+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 167.3% | Better than 92% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 8.87
- Open
- 8.77
- Day range
- 8.34 - 8.92
- Avg price
- 8.55
- Volume
- 3.09M
- Turnover
- 26.40M
- Turnover ratei
- 1.98%
- Volume ratioi
- 0.50
- Amplitudei
- 6.48%
- 52-week rangei
- 5.45 - 14.38
Valuation
- P/Ei
- -2.66
- P/E (TTM)i
- -7.11
- P/Bi
- 1.74
- EPSi
- -3.16
- Book value / shi
- 4.81
- Net profit
- -588.62M
- Net assets
- 895.96M
Share structure
- Market cap
- 1.56B
- Float capi
- 1.31B
- Shares out
- 186.27M
- Float sharesi
- 156.08M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2019-10-11
41.7% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-8.37M net over the window
Short interest
- Shares short
- 16.87M
- % of floati
- 9.97%
- Days to coveri
- 11.86
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Vir Biotechnology (VIR)?
Vir Biotechnology last traded at 8.39. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Vir Biotechnology's market cap?
About 1.56B.
What is the P/E ratio of Vir Biotechnology?
The trailing twelve-month P/E is -7.11. The Valuation tab shows it against the stock's own five-year range.
Does Vir Biotechnology pay a dividend?
Vir Biotechnology does not currently pay a regular dividend.
Is Vir Biotechnology a buy according to analysts?
The consensus of 8 analysts is a Buy rating, with an average 12-month price target of 22.43, which implies 167.3% upside from the current price. This is not investment advice.
What is Vir Biotechnology's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Vir Biotechnology a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Vir Biotechnology discussion 0 comments